Acquired Clotting Factor Deficits During Treatment with Asparaginase in an Institutional Cohort

We invariably see prolongation of activated partial thromboplastin time in patients treated with asparaginase in our clinical practice, but have noted that, contrary to hypofibrinogenemia and low antithrombin, clotting times’ prolongation by asparaginase is largely unreported in the literature and g...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulou, Vasiliki, Schiavini, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641023/
https://www.ncbi.nlm.nih.gov/pubmed/37965639
http://dx.doi.org/10.2147/JBM.S428159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641023/
https://www.ncbi.nlm.nih.gov/pubmed/37965639
http://dx.doi.org/10.2147/JBM.S428159

Ejemplares similares